Bioresorbable vascular stents and drug-eluting stents in treatment of coronary heart disease: a meta-analysis

Ni, Le; Chen, Hao; Luo, Zhen; Yu, Yunqiang

doi:10.1186/s13019-020-1041-5

Cited by 17 publications

(15 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it demonstrates excellent corrosion resistance and fatigue resistance, which are needed in the venous system to prevent stent restenosis. Therefore, iron-based materials have potential in the future application of venous resorbable stents [66,67] . Despite the fact that the initial effort of a BVS in the coronary system was not successful, the obtained experience and knowledge can be applied to its use in the venous system in the near future, since the incidence of late stent thrombosis may be low in the venous system [12] .…”

Section: Bioresorbable Vascular Scaffoldmentioning

confidence: 99%

Current Status and Prospect of Stent Placement for May-Thurner Syndrome

Liu

Lü

et al. 2021

CURR MED SCI

View full text Add to dashboard Cite

Stent implantation has been proven to be safe and has become the first-line intervention for May-Thurner syndrome (MTS), with satisfactory mid-term patency rates and clinical outcomes. Recent research has demonstrated that catheter-directed thrombolysis is the preferred strategy when MTS is combined with deep vein thrombosis after self-expanding stent placement. However, the stent used for the venous system was developed based on the experience obtained in the treatment of arterial disease. Consequently, relatively common corresponding complications may come along later, which include stent displacement, deformation, and obstruction. Different measures such as adopting a stent with a larger diameter, improving stent flexibility, and increasing stent strength have been employed in order to prevent these complications. The ideal venous stent is presently being evaluated and will be introduced in detail in this review.

show abstract

Section: Bioresorbable Vascular Scaffoldmentioning

confidence: 99%

Current Status and Prospect of Stent Placement for May-Thurner Syndrome

Liu

Lü

et al. 2021

CURR MED SCI

View full text Add to dashboard Cite

show abstract

“…It releases everolimus and is fully degraded to H 2 O and CO 2 in 2–3 years. BVS seems to offer several theoretical advantage over metallic stent, as it gives temporary mechanical support of vessel wall; therefore, long-term endothelial function and structure are not affected, and a possible future surgical revascularization is not compromised [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

Long-term follow-up of therapeutic efficacy of everolimus-eluting bioresorbable vascular scaffold in comparison to everolimus-eluting stent in treatment of chronic total occlusion guided by intracoronary imaging

et al. 2020

View full text Add to dashboard Cite

Background We hypothesized that 1st generation everolimus-eluting bioresorbable vascular scaffold (BVS) stent associated with less complication and less restenosis rate than everolimus-eluting stent (EES) in chronic total occlusion (CTO) recanalization guided by intracoronary imaging. Therefore, we aimed to assess the safety and performance of BVS stent in CTO revascularization in comparison to EES guided by intracoronary imaging. Our prospective comparative cross-sectional study was conducted on 60 CTO patients divided into two groups according to type of stent revascularization: group I (EES group): 40 (66.7%) patients and group II (BVS group): 20 (33.3%) patients. All patients were subjected to history taking, electrocardiogram (ECG), echocardiography, laboratory investigation, stress thallium study to assess viability before revascularization. Revascularization of viable CTO lesion guided by intracoronary imaging using optical coherence tomography (OCT). Then, long-term follow-up over 1 year clinically and by multi-slice CT coronary angiography (MSCT). Our clinical and angiographic endpoints were to detect any clinical or angiographic complications during the follow-up period. Results At 6 months angiographic follow-up, BVS group had not inferior angiographic parameters but without statistically significant difference (p = 0.566). At 12 months follow-up, there was no difference at end points between the two groups (p = 0.476). No differences were found at angiographic or clinical follow-up between BVS and EES. Conclusion This study shows that 1st generation everolimus-eluting BVS is non-inferior to EES for CTO revascularization. Further studies are needed to clearly state which new smaller footprint BVS, faster reabsorption, magnesium-based less thrombogenicity, and advanced mechanical properties is under development. We cannot dismiss the efficacy and safety of new BVS technology. Trial registration ZU-IRB#2498/3-12-2016 Registered 3 December 2016, email: IRB_123@medicine.zu.edu.eg

show abstract

“…These types of scaffolds are not permanent, and their main advantage is that they offer temporary mechanical support in the vessel to prevent immediate restenosis and vascular recoil, while the long-term risk of complications due to the metallic stent matrix is eliminated. However, their superiority over DES is not yet clear, as long-term studies have not been conducted [ 9 , 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Bio-Performance of Hydrothermally and Plasma-Treated Titanium: The New Generation of Vascular Stents

Benčina

Rawat

Lakota

et al. 2021

IJMS

View full text Add to dashboard Cite

The research presented herein follows an urgent global need for the development of novel surface engineering techniques that would allow the fabrication of next-generation cardiovascular stents, which would drastically reduce cardiovascular diseases (CVD). The combination of hydrothermal treatment (HT) and treatment with highly reactive oxygen plasma (P) allowed for the formation of an oxygen-rich nanostructured surface. The morphology, surface roughness, chemical composition and wettability of the newly prepared oxide layer on the Ti substrate were characterized by scanning electron microscopy (SEM) with energy-dispersive X-ray analysis (EDX), atomic force microscopy (AFM), X-ray photoelectron spectroscopy (XPS) and water contact angle (WCA) analysis. The alteration of surface characteristics influenced the material’s bio-performance; platelet aggregation and activation was reduced on surfaces treated by hydrothermal treatment, as well as after plasma treatment. Moreover, it was shown that surfaces treated by both treatment procedures (HT and P) promoted the adhesion and proliferation of vascular endothelial cells, while at the same time inhibiting the adhesion and proliferation of vascular smooth muscle cells. The combination of both techniques presents a novel approach for the fabrication of vascular implants, with superior characteristics.

show abstract

Bioresorbable vascular stents and drug-eluting stents in treatment of coronary heart disease: a meta-analysis

Cited by 17 publications

References 28 publications

Current Status and Prospect of Stent Placement for May-Thurner Syndrome

Current Status and Prospect of Stent Placement for May-Thurner Syndrome

Long-term follow-up of therapeutic efficacy of everolimus-eluting bioresorbable vascular scaffold in comparison to everolimus-eluting stent in treatment of chronic total occlusion guided by intracoronary imaging

Bio-Performance of Hydrothermally and Plasma-Treated Titanium: The New Generation of Vascular Stents

Contact Info

Product

Resources

About